Exact Mass: 788.411172
Exact Mass Matches: 788.411172
Found 149 metabolites which its exact mass value is equals to given mass value 788.411172,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Dulcoside A
Dulcoside A is present in Stevia rebaudiana (stevia) extracts. Present in Stevia rebaudiana (stevia) extracts Dulcoside A is isolated from Stevia rebaudiana, it often advertised as a sweetener[1].
Balagyptin
Balagyptin is found in fruits. Balagyptin is a constituent of Balanites aegyptiaca (soapberry tree fruits). Constituent of Balanites aegyptiaca (soapberry tree fruits). Balagyptin is found in fruits.
PGP(a-13:0/i-18:0)
PGP(a-13:0/i-18:0) is a phosphatidylglycerophosphate (PGP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site followed by another phosphate moiety. Phosphatidylglycerolphosphate is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerolphosphate increases during fetal development. Phosphatidylglycerolphosphate may be present in animal tissues merely as a precursor for cardiolipin synthesis. As is the case with diacylglycerols, phosphatidylglycerophosphates can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PGP(a-13:0/i-18:0), in particular, consists of one chain of anteisotridecanoic acid at the C-1 position and one chain of isooctadecanoic acid at the C-2 position. They are synthesized by the addition of glycerol 3-phosphate to a CDP-diacylglycerol. In turn, PGPs are dephosphorylated to phosphatidylglycerols (PGs). While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes.
PGP(i-12:0/i-19:0)
PGP(i-12:0/i-19:0) is a phosphatidylglycerophosphate (PGP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site followed by another phosphate moiety. Phosphatidylglycerolphosphate is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerolphosphate increases during fetal development. Phosphatidylglycerolphosphate may be present in animal tissues merely as a precursor for cardiolipin synthesis. As is the case with diacylglycerols, phosphatidylglycerophosphates can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PGP(i-12:0/i-19:0), in particular, consists of one chain of isododecanoic acid at the C-1 position and one chain of isononadecanoic acid at the C-2 position. They are synthesized by the addition of glycerol 3-phosphate to a CDP-diacylglycerol. In turn, PGPs are dephosphorylated to phosphatidylglycerols (PGs). While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes.
PGP(i-13:0/i-18:0)
PGP(i-13:0/i-18:0) is a phosphatidylglycerophosphate (PGP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site followed by another phosphate moiety. Phosphatidylglycerolphosphate is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerolphosphate increases during fetal development. Phosphatidylglycerolphosphate may be present in animal tissues merely as a precursor for cardiolipin synthesis. As is the case with diacylglycerols, phosphatidylglycerophosphates can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PGP(i-13:0/i-18:0), in particular, consists of one chain of isotridecanoic acid at the C-1 position and one chain of isooctadecanoic acid at the C-2 position. They are synthesized by the addition of glycerol 3-phosphate to a CDP-diacylglycerol. In turn, PGPs are dephosphorylated to phosphatidylglycerols (PGs). While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes.
PGP(i-14:0/a-17:0)
PGP(i-14:0/a-17:0) is a phosphatidylglycerophosphate (PGP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site followed by another phosphate moiety. Phosphatidylglycerolphosphate is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerolphosphate increases during fetal development. Phosphatidylglycerolphosphate may be present in animal tissues merely as a precursor for cardiolipin synthesis. As is the case with diacylglycerols, phosphatidylglycerophosphates can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PGP(i-14:0/a-17:0), in particular, consists of one chain of isotetradecanoic acid at the C-1 position and one chain of anteisoheptadecanoic acid at the C-2 position. They are synthesized by the addition of glycerol 3-phosphate to a CDP-diacylglycerol. In turn, PGPs are dephosphorylated to phosphatidylglycerols (PGs). While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes.
PGP(i-14:0/i-17:0)
PGP(i-14:0/i-17:0) is a phosphatidylglycerophosphate (PGP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site followed by another phosphate moiety. Phosphatidylglycerolphosphate is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerolphosphate increases during fetal development. Phosphatidylglycerolphosphate may be present in animal tissues merely as a precursor for cardiolipin synthesis. As is the case with diacylglycerols, phosphatidylglycerophosphates can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PGP(i-14:0/i-17:0), in particular, consists of one chain of isotetradecanoic acid at the C-1 position and one chain of isoheptadecanoic acid at the C-2 position. They are synthesized by the addition of glycerol 3-phosphate to a CDP-diacylglycerol. In turn, PGPs are dephosphorylated to phosphatidylglycerols (PGs). While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes.
PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:5(5Z,8Z,11Z,14Z,17Z))
PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:5(5Z,8Z,11Z,14Z,17Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PG(i-14:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
C40H69O13P (788.4475553999999)
PG(i-14:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(i-14:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).
PG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-14:0)
C40H69O13P (788.4475553999999)
PG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-14:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-14:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).
dulcoside B
[Chemical] Source; leaves of Stevia rebaudiana Morita and Stevia rebaudiana Bertoni
(20R,24R,22E)-28-O-[3-O-methyl-beta-D-xylopyranosyl-(1->4)-3-O-methyl-beta-D-xylopyranosyl]-24-methyl-5alpha-cholest-22-ene-3beta,4beta,6alpha,8,15beta,16beta,28-heptaol|milleporoside B
(3beta,20S)-3,17-dihydoxypregn-5-en-20-yl O-beta-glucopyranosyl-(1->4)-O-beta-glucopyranosyl-(1->4)-2,6-dideoxy-beta-xylo-hexopyranoside|(3beta,20S)-pregn-5-ene-3,17,20-triol 20-[O-beta-glucopyranosyl-(1->6)-O-beta-glucopyranosyl-(1->4)-beta-canaropyranoside]
(25R)-ruscogenin 1-O-alpha-L-rhamnopyranosyl-(1->2)-4-O-sulfo-beta-D-arabinopyranoside|ruscogenin 1-O-alpha-L-rhamnopyranosyl(1->2)-4-O-sulfo-alpha-L-arabinopyranoside
26-O-beta-D-glucopyranosyl-22-O-methyl-25(S)-5alpha-forostan-1beta,3alpha,22zeta,26-tetrol 3-O-beta-D-glucopyranoside
permethylated beta-Rha-(1-3)-beta-Glc-(1-2)-(alpha-Rha-(1-3))-Rhaol|permethylated beta-Rha-(1-3)-beta-Glc-(1-2)--Rhaol
26-O-beta-D-glucopyranosyl-22alpha-hydroxy-5beta-furost-25(27)ene-1beta,3beta,6beta,26-tetraol-3-O-beta-D-galactopyranoside
Dulcoside A
Dulcoside A is a diterpene glycoside. Dulcoside A is a natural product found in Stevia rebaudiana with data available. See also: Stevia rebaudiuna Leaf (part of). [Chemical] Source; leaves of Stevia rebaudiana Morita and Stevia rebaudiana Bertoni Dulcoside A is isolated from Stevia rebaudiana, it often advertised as a sweetener[1].
PI(13:0/18:4(6Z,9Z,12Z,15Z))
C40H69O13P (788.4475553999999)
PI(18:4(6Z,9Z,12Z,15Z)/13:0)
C40H69O13P (788.4475553999999)
Balagyptin
PI 31:4
C40H69O13P (788.4475553999999)
26-O-beta-d-glucopyranosyl-(22S, 25S)-furostan-22,25-epoxy-1beta,3beta,5beta,26-tetrol-3-O-beta-d-glucopyranoside
26-O-beta-d-glucopyranosyl-(22S, 25S)-furostan-22,25-epoxy-1beta,3alpha,5beta,26-tetrol-3-O-beta-d-glucopyranoside
26-O-beta-d-glucopyranosyl-(22S,25S)-furostan-22,25-epoxy-3beta,5beta,26,27-tetrol-5-O-beta-d-glucopyranoside
4,4,4-Tris(N-3-methylphenyl-N-phenylamino)triphenylamine
3-O-(Glcb)-6-O-(Glcb)-(25R)-5alpha-spirostan-3beta,6alpha,23S-triol
(1R,4S,5R,9S,10R,13S)-13-[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylic acid
PG(i-14:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
C40H69O13P (788.4475553999999)
PG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-14:0)
C40H69O13P (788.4475553999999)
PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:5(5Z,8Z,11Z,14Z,17Z))
S-(3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl)-4-phosphopantetheine(2-)
C38H65N2O11PS-2 (788.4046470000001)
[1-propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
[1-nonanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-nonanoyloxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
C40H69O13P (788.4475553999999)
[1-heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate
C40H69O13P (788.4475553999999)
[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
C40H69O13P (788.4475553999999)
[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
C40H69O13P (788.4475553999999)
[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
C40H69O13P (788.4475553999999)
[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
C40H69O13P (788.4475553999999)
[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
C40H69O13P (788.4475553999999)
[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate
C40H69O13P (788.4475553999999)
[(2S)-3-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-undecanoyloxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate
C40H69O13P (788.4475553999999)
[(2R)-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-tridecanoyloxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate
C40H69O13P (788.4475553999999)
[(2R)-1-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate
C40H69O13P (788.4475553999999)
[1-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate
C40H69O13P (788.4475553999999)
(1R,4S,5R,9S,10R,13S)-13-[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylic acid
[(2R)-1-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate
C40H69O13P (788.4475553999999)
[1-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate
C40H69O13P (788.4475553999999)
[(2R)-1-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate
C40H69O13P (788.4475553999999)
[(2S)-3-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-undecanoyloxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate
C40H69O13P (788.4475553999999)
[(2R)-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-tridecanoyloxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate
C40H69O13P (788.4475553999999)
[(2R)-1-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate
C40H69O13P (788.4475553999999)
[1-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate
C40H69O13P (788.4475553999999)
S-(3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl)-4-phosphopantetheine(2-)
C38H65N2O11PS (788.4046470000001)
An S-acyl-4-phosphopantetheine obtained by deprotonation of the phosphate OH groups of S-(3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl)-4-phosphopantetheine; major species at pH 7.3.
(2e)-n-[(2s,3r,4r,5r,6r)-2-{[(2s,3s,4s,5r,6s)-4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-6-[(2r)-2-[(2r,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-10-methylundec-2-enimidic acid
(2s,4as,4br,7r,10ar)-2-{[(2r,3r,4s,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-7-ethenyl-1,1,4a,7-tetramethyl-2,3,4,4b,5,6,10,10a-octahydrophenanthren-9-one
(2r,3r,4s,5s,6r)-2-[(2r)-4-[(1s,2s,4s,6r,7s,8r,9s,12s,13s,14r,16s,18s)-14-hydroxy-6-methoxy-7,9,13-trimethyl-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6-yl]-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
2-[4-(14-hydroxy-6-methoxy-7,9,13-trimethyl-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6-yl)-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
agamenoside h
{"Ingredient_id": "HBIN014815","Ingredient_name": "agamenoside h","Alias": "NA","Ingredient_formula": "C39H64O16","Ingredient_Smile": "CC1COC2(C(C3C(O2)CC4C3(CCC5C4CC(C6C5(CCC(C6)O)C)OC7C(C(C(C(O7)CO)O)O)O)C)C)C(C1OC8C(C(C(C(O8)CO)O)O)O)O","Ingredient_weight": "788.9 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "697","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "11331778","DrugBank_id": "NA"}
2-{[4,5-dihydroxy-2-(hydroxymethyl)-6-[5-(hydroxymethyl)-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-15',19'-dioloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2s,3r,4s,5r,6r)-4-{[(2s,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-hydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl (1s,4s,5r,9r,10r,11s,13s,14s)-5,9,13-trimethyl-12-oxapentacyclo[11.2.1.1¹¹,¹⁴.0¹,¹⁰.0⁴,⁹]heptadecane-5-carboxylate
1-[7-({3-[(4,5-dihydroxy-3-methoxyoxan-2-yl)oxy]-5-(1,2-dihydroxyethyl)-4-hydroxyoxolan-2-yl}oxy)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,6,7-pentol
(1r,2r,3s,3as,3bs,5s,5ar,6r,7s,9as,9br,11ar)-1-[(2r,3e,5r)-5-({[(2r,3r,4r,5r)-5-{[(2s,3r,4s,5r)-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy}-3-hydroxy-4-methoxyoxan-2-yl]oxy}methyl)-6-methylhept-3-en-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-2,3,3b,5,6,7-hexol
(2s,3r,4s,5s,6r)-2-{[(2r,3s,4r,6s)-6-[(1s)-1-[(1r,3as,3br,7s,9ar,9bs,11as)-1,7-dihydroxy-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethoxy]-4-hydroxy-2-methyloxan-3-yl]oxy}-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol
(1s,2s,4s,6r,7s,8r,9s,12s,13s,14r,16s,18s)-7,9,13-trimethyl-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-[3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,14,18-triol
6-[(2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl)oxy]-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-6-{[3,5-dihydroxy-6-(hydroxymethyl)-4-oxooxan-2-yl]oxy}-2,6-dimethylocta-2,7-dienoate
1-{5-[({3-[(4,5-dihydroxy-3-methoxyoxan-2-yl)oxy]-5-(1,2-dihydroxyethyl)-4-hydroxyoxolan-2-yl}oxy)methyl]-6-methylhept-3-en-2-yl}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-2,3,3b,5,7-pentol
n-[(2r,8s,11s,14s,17s,20r,21s)-2-benzyl-6,12-dihydroxy-14-[(1r)-1-hydroxy-2-methylpropyl]-17-[(1r)-1-methoxyethyl]-4,8,10,11,16,20-hexamethyl-5-methylidene-3,9,15,18,22-pentaoxo-1,19-dioxa-4,7,10,13,16-pentaazacyclodocosa-6,12-dien-21-yl]ethanimidic acid
C38H56N6O12 (788.3956016000001)
2-{[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-7-ethenyl-1,1,4a,7-tetramethyl-2,3,4,4b,5,6,10,10a-octahydrophenanthren-9-one
(2r,3r,4r,5r,6s)-2-{[(2r,3s,4s,5r,6r)-6-{[(1s,2s,3as,3bs,7s,9ar,9bs,11as)-2-hydroxy-1-[(1s)-1-hydroxyethyl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4-dihydroxy-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]methoxy}-6-methyloxane-3,4,5-triol
(2e)-n-[(2r,3s,4s,5r,6s)-2-{[(2s,3s,4r,5s,6s)-4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-6-[(2s)-2-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-10-methylundec-2-enimidic acid
(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5s,7's,8'r,9's,12's,13'r,15'r,16'r,18's,19'r)-5-(hydroxymethyl)-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-15',19'-dioloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2e)-n-[(2s,3r,4r,5r,6r)-2-{[(2s,3s,4s,5r,6s)-4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-6-[(2r)-2-[(2r,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]dodec-2-enimidic acid
2-{[6-(1-{1,7-dihydroxy-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethoxy)-4-hydroxy-2-methyloxan-3-yl]oxy}-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol
(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1r,4s,5r,9s,10r,13s)-5,9-dimethyl-14-methylidene-13-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2e)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy}methyl)oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate
(2s,3r,4s,5r,6s)-6-{[(2s,3r,4s,5s,6r)-2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-6-{[(2s,3s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-oxooxan-2-yl]oxy}-2,6-dimethylocta-2,7-dienoate
1,3-bis({8a-[(acetyloxy)methyl]-5-[2-(furan-3-yl)ethyl]-5,6-dimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl}methyl) propanedioate
6-({2-[(3,7-dimethylocta-1,6-dien-3-yl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxy)-4,5-dihydroxy-2-methyloxan-3-yl 6-{[3,5-dihydroxy-6-(hydroxymethyl)-4-oxooxan-2-yl]oxy}-2,6-dimethylocta-2,7-dienoate
(1r,2r,3s,3as,3bs,5s,5as,6r,7s,9as,9br,11ar)-1-[(2r,3e,5r)-5-(2-{[(2r,3r,4r,5r)-3-hydroxy-4-methoxy-5-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}ethyl)-6-methylhept-3-en-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-2,3,3b,5,6,7-hexol
[(3s,4r,5r,6s)-4-hydroxy-6-[(1's,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,14'r,16'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy]-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl]oxidanesulfonic acid
1-{5-[({5-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxy]-3-hydroxy-4-methoxyoxan-2-yl}oxy)methyl]-6-methylhept-3-en-2-yl}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-2,3,3b,5,6,7-hexol
n-[2-({4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl}oxy)-6-{2-[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]-2-hydroxyethyl}-4,5-dihydroxyoxan-3-yl]dodec-2-enimidic acid
(1r,3r,3as,3bs,5s,5as,6r,7s,9as,9br,11ar)-1-[(2r,3e,5s,6r)-7-{[(2r,3r,4s,5s)-3-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy}-5-[(1r)-1,2-dihydroxyethyl]-4-hydroxyoxolan-2-yl]oxy}-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,6,7-pentol
(2s,4as,4br,7r,10ar)-2-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-7-ethenyl-1,1,4a,7-tetramethyl-2,3,4,4b,5,6,10,10a-octahydrophenanthren-9-one
(2s)-2-{2-[(2-hydroxy-3-methylbutanoyl)oxy]-n,3-dimethylbutanamido}-n-[(1s,2s)-1-{[(1s)-1-{[(2s)-1-[(2s)-2-(methoxycarbonyl)pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}-2-methylbutyl]butanediimidic acid
(1r,3s,3as,3bs,5r,5as,6r,7s,9as,9br,11ar)-1-[(2r,5r)-5-{[(2r,3r,4r,5s)-4-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-6-methylheptan-2-yl]-3b,5,6,7-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-3-yl acetate
(2s,3r,4s,5r,6r)-2-{[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,15'r,16'r,18's,19'r)-5-(hydroxymethyl)-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-15',19'-dioloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(1r,5s,8r,9s,13r,17s,18r,22s,25r,26s,30r,34s)-9,26-bis(carboxymethyl)-13,17,30,34-tetramethyl-4,21-dimethylidene-10,27-dioxo-7,11,24,28-tetraoxapentacyclo[28.4.0.0⁵,³⁴.0¹³,¹⁸.0¹⁷,²²]tetratriacontane-8,25-dicarboxylic acid
1,3-bis{[(4ar,5s,6r,8as)-8a-[(acetyloxy)methyl]-5-[2-(furan-3-yl)ethyl]-5,6-dimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl} propanedioate
n-[2-({4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl}oxy)-6-{2-[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]-2-hydroxyethyl}-4,5-dihydroxyoxan-3-yl]-10-methylundec-2-enimidic acid
(2r,3r,4s,5r,6r)-2-(hydroxymethyl)-6-[(1'r,2s,2's,3s,4r,4's,5s,7's,8'r,9's,12's,13'r,16's,18's,19's)-5,7',9',13'-tetramethyl-4-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-3,16'-dioloxy]oxane-3,4,5-triol
7,9,13-trimethyl-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-[3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,14,18-triol
9,26-bis(carboxymethyl)-13,17,30,34-tetramethyl-4,21-dimethylidene-10,27-dioxo-7,11,24,28-tetraoxapentacyclo[28.4.0.0⁵,³⁴.0¹³,¹⁸.0¹⁷,²²]tetratriacontane-8,25-dicarboxylic acid
(4-hydroxy-6-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy}-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-3-yl)oxidanesulfonic acid
3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 5,9-dimethyl-14-methylidene-13-{[3,4,5-trihydroxy-6-({[3-(4-hydroxyphenyl)prop-2-enoyl]oxy}methyl)oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate
1-[5-({4-[(4,5-dihydroxy-3-methoxyoxan-2-yl)oxy]-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl}oxy)-6-methylheptan-2-yl]-3b,5,6,7-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-3-yl acetate
(1r,5s,8r,9r,13r,17s,18r,22s,25r,26s,30r,34s)-9,26-bis(carboxymethyl)-13,17,30,34-tetramethyl-4,21-dimethylidene-10,27-dioxo-7,11,24,28-tetraoxapentacyclo[28.4.0.0⁵,³⁴.0¹³,¹⁸.0¹⁷,²²]tetratriacontane-8,25-dicarboxylic acid
n-[2-benzyl-6,12-dihydroxy-14-(1-hydroxy-2-methylpropyl)-17-(1-methoxyethyl)-4,8,10,11,16,20-hexamethyl-5-methylidene-3,9,15,18,22-pentaoxo-1,19-dioxa-4,7,10,13,16-pentaazacyclodocosa-6,12-dien-21-yl]ethanimidic acid
C38H56N6O12 (788.3956016000001)